EUCTR2022-004195-42-AT招募中1 期
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Populations of Interest - FIT-05
ELGAN Pharma0 个研究点目标入组 360 人开始时间: 2023年5月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female pre-term infants 26 and up to 32 weeks gestation (32 weeks + 0 day maximum). Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound*.
- •2. Birth weight = 500g.
- •3. Singleton, or twin birth.
- •4. Postnatal age up through and including Day 5 (up to 120 hours post birth).
- •5. Fraction of inspired oxygen = 0.60 at enrolment.
- •6. Infants must demonstrate cardiovascular stability at time of enrolment and would be considered unstable if they require blood pressure support via a central line.
- •7. Infant is able to tolerate enteral feed.
- •8. Infant is expected to wean off PN at the primary hospital.
- •9. Informed consent form (ICF) signed by parents or legal guardian.
- •10. In the Investigator’s opinion, the infant is able to comply with the study procedures and sufficiently stable to partake in the trial to completion.
- •* If both exist and difference > 2 weeks, based on early antenatal ultrasound
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 360
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Infant is consuming more than 100 ml/kg/day enterally at study entry
- •2. Infant is not dependent on any parenteral amino acids/lipids as nutrition
- •3. Major congenital malformation (e.g., Infants with genetic, metabolic, and/or endocrine disorder diagnosed before enrolment).
- •4. Intra-uterine growth restriction (IUGR) defined as weight for gestational age less than the third percentile according to Fenton preterm growth chart (see Appendix D).
- •5. Confirmed necrotizing enterocolitis (NEC).1
- •6. Maternal diabetes (Type I/II or gestational) requiring insulin during pregnancy or in mothers past medical history.
- •7. suspected or confirmed Hyperinsulinemia requiring glucose administration of more than 12 mg/kg/min at randomization.
- •8. Any systemic insulin administration at randomization.
- •9. Never anything per os (NPO) until 120 hrs post-birth for any reason.
- •10. Heart and chest compression or any resuscitation drugs given to the infant during delivery.
- •11. Subjects at risk for significant GI complications such as twin-to-twin transfusion syndrome (TTTS) or monochorionic monoamniotic twins.
- •12. Participation in another interventional clinical study that may interfere with the primary and secondary outcomes of this trial.
研究者
相似试验
招募中
1 期
A research study to evaluate if ELGN-2112 is effective and safe for the treatment of Intestinal Malabsorption in Preterm InfantsIntestinal Malabsorption in Preterm InfantsMedDRA version: 20.0Level: LLTClassification code 10032413Term: Other preterm infants, 750-999 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032407Term: Other preterm infants, 1,250-1,499 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032409Term: Other preterm infants, 1,750-1,999 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032411Term: Other preterm infants, 2,500+ gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032415Term: Other preterm infants, unspecified {weight}System Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032412Term: Other preterm infants, 500-749 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032406Term: Other preterm infants, 1,000-1,249 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032408Term: Other preterm infants, 1,500-1,749 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032410Term: Other preterm infants, 2,000-2,499 gramsSystem Organ Class: 100000004868EUCTR2021-004890-29-ATELGAN Pharma360
进行中（未招募）
1 期
study that will be conduced in different clinical sites, in which nor the patient neither the doctors will know the treatment given to patient, with 2 different group in which the patients will be assigned randomly, controlled with respect to placebo, that has the aim to estabilish the efficacy and the safety of ELGN2112 on the incapability of preterm baby to absorb sufficient nutrients, a condition known as intestinal malabsorptioIntestinal Malabsorption in Preterm InfantsMedDRA version: 20.0Level: LLTClassification code 10032413Term: Other preterm infants, 750-999 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032407Term: Other preterm infants, 1,250-1,499 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032409Term: Other preterm infants, 1,750-1,999 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032411Term: Other preterm infants, 2,500+ gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032415Term: Other preterm infants, unspecified {weight}System Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032412Term: Other preterm infants, 500-749 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032406Term: Other preterm infants, 1,000-1,249 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032408Term: Other preterm infants, 1,500-1,749 gramsSystem Organ Class: 100000004868MedDRA version: 20.0Level: LLTClassification code 10032410Term: Other preterm infants, 2,000-2,499 gramsSystem Organ Class: 100000004868EUCTR2021-004890-29-SEELGAN Pharma360
尚未招募
2 期
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Populations of InterestPrematurity - preterm birthfeeding intoleranceintestinal malabsorption in preterm infants10025477NL-OMON53321ELGAN Pharma10
尚未招募
3 期
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm InfantsPrematurity - preterm birthfeeding intoleranceintestinal malabsorption in preterm infants10025477NL-OMON53803ELGAN Pharma70
已完成
不适用
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaPER-056-07BRISTOL MYERS SQUIBB PERU S.A.,